Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $185 from $175 and keeps an Equal Weight rating on the shares. The company’s “strong” Q1 reinforces Quest “as a ...

A recently published study has identified collagen type X α 1 chain (CoL10A1) as a promising target for treating brain metastasis in breast cancer patients. The research, conducted by a team at First ...

Truist analyst David MacDonald raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $182 and keeps a Hold rating on the shares on the heels of solid Q1 results featuring in ...

Apr. 25, 2025 — Astronomers have discovered that super-Earth exoplanets are more common across the universe than previously thought. While it can be relatively easy to locate worlds that orbit ...

Additionally, BCB-276 keeps the blood-brain barrier intact and minimizes any on-target, off-tumor toxicities. The phase 1 BrainChild-03 is enrolling patients between the ages of 1 and 26 years with ...

Ferry operators opened up on how they aim to decarbonise their fleets at the latest Interferry conference Ferry operators and industry insiders highlighted how they aim to meet net-zero requirements ...

November 25, 2024 • Books We Love returns with 350+ new titles handpicked by NPR staff and trusted critics. Find 12 years of recommendations all in one place — that's nearly 4,000 great reads.

We’re sorry, this feature is currently unavailable. We’re working to restore it. Please try again later.